{"id":"rc48-adc","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL3810342","moleculeType":"Small molecule","molecularWeight":"405.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RC48-ADC combines a humanized anti-HER2 monoclonal antibody with a microtubule-disrupting cytotoxic agent (monomethyl auristatin E, MMAE) via a cleavable linker. The antibody binds to HER2 on cancer cell surfaces, enabling internalization and release of the toxic payload within tumor cells, leading to cell cycle arrest and apoptosis while sparing HER2-negative cells.","oneSentence":"RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:17.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive gastric cancer"},{"name":"HER2-positive breast cancer"},{"name":"HER2-positive biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT06966453","phase":"PHASE1, PHASE2","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-06-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":100},{"nctId":"NCT06157892","phase":"PHASE2","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2024-05-20","conditions":"Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms","enrollment":172},{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT06003231","phase":"PHASE2","title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-11-14","conditions":"Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms","enrollment":120},{"nctId":"NCT07366840","phase":"PHASE2, PHASE3","title":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":268},{"nctId":"NCT04879329","phase":"PHASE2","title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-05-03","conditions":"Urothelial Carcinoma","enrollment":372},{"nctId":"NCT05837806","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-12-30","conditions":"Neoadjuvant Immunotherapy","enrollment":21},{"nctId":"NCT07279597","phase":"PHASE2","title":"A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-10","conditions":"Muscle-invasive Bladder Urothelial Carcinoma","enrollment":45},{"nctId":"NCT06210490","phase":"PHASE2","title":"A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-02-20","conditions":"Upper Urinary Tract Urothelial Carcinoma","enrollment":60},{"nctId":"NCT05831878","phase":"NA","title":"RC48-ADC in HER2-low Advanced Breast Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-05-04","conditions":"Advanced Breast Cancer","enrollment":36},{"nctId":"NCT07201675","phase":"PHASE2","title":"Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-12-01","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":59},{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT05851677","phase":"","title":"Disitamab Vedotin (RC48-ADC) in Breast Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07151560","phase":"PHASE2","title":"Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Renmin Hospital of Wuhan University","startDate":"2025-08-30","conditions":"Urology","enrollment":60},{"nctId":"NCT06957561","phase":"PHASE1, PHASE2","title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Bladder Cancer, Muscle-invasive Bladder Cancer","enrollment":30},{"nctId":"NCT06798246","phase":"","title":"HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-02-01","conditions":"Upper Tract Urothelial Carcinoma","enrollment":200},{"nctId":"NCT06791070","phase":"PHASE2","title":"A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-01","conditions":"Paget Disease, Extramammary, Scrotum Disease","enrollment":20},{"nctId":"NCT05917158","phase":"PHASE2","title":"A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma","status":"RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2022-11-23","conditions":"Carcinoma, Upper Tract Urothelial Carcinoma, UTUC","enrollment":30},{"nctId":"NCT06341400","phase":"PHASE1, PHASE2","title":"RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2024-06-19","conditions":"Bladder Cancer, Muscle-Invasive Bladder Carcinoma","enrollment":55},{"nctId":"NCT06572319","phase":"PHASE1, PHASE2","title":"Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-09-01","conditions":"HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":35},{"nctId":"NCT06105008","phase":"PHASE2","title":"Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"RemeGen Co., Ltd.","startDate":"2024-12-20","conditions":"Breast Neoplasms","enrollment":""},{"nctId":"NCT06560528","phase":"PHASE2","title":"Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06155396","phase":"PHASE2","title":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-01-11","conditions":"Cervical Cancer","enrollment":116},{"nctId":"NCT05135715","phase":"PHASE2","title":"A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-04-19","conditions":"Melanoma, Stage II, HER2-positive, Advanced Melanoma","enrollment":50},{"nctId":"NCT05297552","phase":"PHASE2","title":"A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-26","conditions":"Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT03500380","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2018-04-24","conditions":"Breast Neoplasms, Breast Diseases, Capecitabine","enrollment":301},{"nctId":"NCT04400695","phase":"PHASE3","title":"A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-09-29","conditions":"Breast Cancer","enrollment":366},{"nctId":"NCT05403242","phase":"PHASE1, PHASE2","title":"RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2022-09-20","conditions":"Advanced Gastroesophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT04714190","phase":"PHASE3","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-24","conditions":"Gastric Cancer, HER2 Overexpressing Gastric Carcinoma","enrollment":351},{"nctId":"NCT06178601","phase":"PHASE2","title":"A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2023-08-03","conditions":"Urothelial Carcinoma","enrollment":36},{"nctId":"NCT04329429","phase":"PHASE2","title":"A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-08-24","conditions":"Biliary Tract Cancer","enrollment":57},{"nctId":"NCT04965519","phase":"PHASE2","title":"A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-12-21","conditions":"Gynecological Malignancy","enrollment":120},{"nctId":"NCT04311034","phase":"PHASE1, PHASE2","title":"A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2018-09-26","conditions":"Non Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT05514158","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-09-28","conditions":"Gastric Cancer","enrollment":24},{"nctId":"NCT05302284","phase":"PHASE3","title":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2022-06-14","conditions":"Urothelial Carcinoma, HER2-expressing","enrollment":452},{"nctId":"NCT03052634","phase":"PHASE1, PHASE2","title":"A Study of RC48-ADC in Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2016-12-23","conditions":"Advanced Breast Cancer","enrollment":112},{"nctId":"NCT04073602","phase":"PHASE2","title":"A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-08-19","conditions":"Urothelial Carcinoma","enrollment":19},{"nctId":"NCT06168227","phase":"","title":"A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-10-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05578287","phase":"PHASE2","title":"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-07-18","conditions":"Colorectal Cancer","enrollment":29},{"nctId":"NCT05745740","phase":"PHASE1, PHASE2","title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04","conditions":"Non-small Cell Lung Cancer","enrollment":26},{"nctId":"NCT05940896","phase":"PHASE1","title":"RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-06-29","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT03809013","phase":"PHASE2","title":"A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-01-07","conditions":"Urothelial Carcinoma","enrollment":64},{"nctId":"NCT06112041","phase":"PHASE2","title":"The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-10-25","conditions":"Carcinoma, Solid Tumor","enrollment":29},{"nctId":"NCT05785325","phase":"PHASE2","title":"RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-08-20","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06074484","phase":"PHASE2","title":"A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-10","conditions":"Muscle Invasive Bladder Carcinoma","enrollment":36},{"nctId":"NCT05979740","phase":"PHASE2","title":"RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy","enrollment":6},{"nctId":"NCT04280341","phase":"PHASE1","title":"JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Peking University","startDate":"2020-06-03","conditions":"HER2-Positive Solid Tumors","enrollment":50},{"nctId":"NCT05996952","phase":"PHASE2","title":"RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-08","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":77},{"nctId":"NCT05955209","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-08-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT05943379","phase":"PHASE2","title":"RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-06-08","conditions":"NMIBC","enrollment":85},{"nctId":"NCT05928897","phase":"PHASE2","title":"Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-01","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT05904964","phase":"PHASE3","title":"Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"HR Positive/HER2 Low Expression Metastatic Breast Cancer","enrollment":288},{"nctId":"NCT05601401","phase":"PHASE2","title":"Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-03-31","conditions":"Salivary Gland Tumors","enrollment":10},{"nctId":"NCT05417230","phase":"PHASE2","title":"RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-08","conditions":"Biliary Tract Cancer","enrollment":29},{"nctId":"NCT05356351","phase":"PHASE2","title":"An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-05-01","conditions":"Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance","enrollment":30},{"nctId":"NCT05331326","phase":"PHASE2","title":"A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-04","conditions":"Metastatic Breast Cancer","enrollment":64},{"nctId":"NCT03556345","phase":"PHASE2","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2018-07-10","conditions":"Gastric Cancer, HER2 Overexpressing Gastric Carcinoma","enrollment":127},{"nctId":"NCT05134519","phase":"PHASE2","title":"RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-11-26","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":20},{"nctId":"NCT05115500","phase":"PHASE2","title":"ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2021-11-01","conditions":"Carcinoma, Solid Tumor","enrollment":55},{"nctId":"NCT05016973","phase":"PHASE2","title":"A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-10-01","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT02881138","phase":"PHASE1","title":"A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2016-03-01","conditions":"Solid Tumors","enrollment":24},{"nctId":"NCT02881190","phase":"PHASE1","title":"Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12-14","conditions":"Solid Tumors","enrollment":57},{"nctId":"NCT04264936","phase":"PHASE1, PHASE2","title":"A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-02-15","conditions":"Urothelial Carcinoma","enrollment":36},{"nctId":"NCT03507166","phase":"PHASE2","title":"A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-12-28","conditions":"Urothelial Carcinoma, Advanced Cancer","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RC48-ADC injection","Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection","RC48","Disitamab Vedotin","Disitamab vedotin"],"phase":"phase_3","status":"active","brandName":"RC48-ADC","genericName":"RC48-ADC","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor. Used for HER2-positive gastric cancer, HER2-positive breast cancer, HER2-positive biliary tract cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":11,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}